Insider Transactions in Q4 2025 at Glycomimetics Inc (GLYC)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 15
2025
|
Richard William Scalzo Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,422
+35.24%
|
-
|
|
Dec 15
2025
|
Joshua T Brumm Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,117
+7.79%
|
-
|
|
Dec 15
2025
|
Christopher Grant Doughty Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,714
+16.38%
|
-
|
|
Dec 15
2025
|
Jan Pinkas Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,507
+34.09%
|
-
|
|
Dec 15
2025
|
Ellie Eunkyung Im Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,298
+34.51%
|
-
|
|
Dec 15
2025
|
Jonathan Mc Neill President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
25,507
+7.44%
|
-
|
|
Dec 15
2025
|
Barbara Harlin Bispham Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,422
+37.28%
|
-
|
|
Dec 15
2025
|
Ryan Lynch Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,378
+37.21%
|
-
|
|
Dec 04
2025
|
Fairmount Funds Management LLC Director |
BUY
Open market or private purchase
|
Indirect |
1,360,000
+33.11%
|
$17,680,000
$13.41 P/Share
|